External Reports and Resources
03 Apr 2025

Online Education about Chemotherapy-Induced Nausea and Vomiting – Empowering Cancer Nurses

Juniper Biologics are excited to introduce a new online learning opportunity for CNSA members: “Chemotherapy-Induced Nausea and Vomiting (CINV): An Essential Update”. This ACN-endorsed course is tailored for nurses managing patients undergoing chemotherapy and includes: 2 CPD points, 3 short modules (2 hours total), interactive case studies and downloadable tools. By completing this education, nurses will deepen their understanding of the pathophysiology of CINV, current management goals, and evidence-based strategies to support optimal patient outcomes.

Cancer nurses play a critical role in helping patients navigate the challenges of chemotherapy and managing chemotherapy-induced nausea and vomiting (CINV) remains one of the most important aspects of supportive care. Despite advances in anti-cancer treatments, CINV continues to affect patient quality of life and treatment adherence.

To support nurses in delivering optimal care, Juniper Biologics is proud to offer an online education program: CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING (CINV): AN ESSENTIAL UPDATE.

This ACN-endorsed course is designed specifically for nurses caring for patients undergoing chemotherapy and offers:

  • 2 Continuing Professional Development (CPD) points
  • 3 concise modules (approx. 2 hours total)
  • Interactive case studies
  • Downloadable tools

Participants will deepen their understanding of the pathophysiology of CINV, current management goals, and evidence-based therapy approaches.

By completing this course, nurses can gain practical knowledge and tools to improve patient outcomes, contribute to better quality of life for those undergoing cancer treatment, and enhance their own professional development.

Click here to access the course and start learning

Akynzeo®: One dose, 5 days relief. Prevention made simple

Akynzeo® (capsule: netupitant 300 mg / palonosetron 0.5 mg; IV: fosnetupitant 235 mg / palonosetron 0.25 mg) is the first and only antiemetic to target two distinct pathways.4-5

Akynzeo® prevents both acute and delayed phases of CINV in a single-dose regimen that delivers up to 5 days of protection. Available in both oral and IV formulations, Akynzeo® is a convenient, guideline-endorsed option for patients receiving moderately to highly anti-cancer therapy.1-5

Importantly, Akynzeo® is PBS-listed for a broad range of anticancer regimens, including newer agents such as Sacituzumab Govitecan, Trastuzumab Deruxtecan, and Selinexor. This expanded reimbursement ensures more patients can benefit from optimal antiemetic protection.6-7

Sincerely,

Juniper Biologics

Related topics

Chemotherapy
Return to listing